The United States dominates the global pharmaceutical market like no other country in the world. According to the healthcare intelligence company , the U.S. alone accounted for nearly half of all worldwide prescription drug sales in 2024, generating almost $800 billion in revenue, within a global pharma market estimated at $1.7 trillion. As our infographic shows, the U.S. dwarfs the four other major national markets: China ($113 billion, hospital market only), Germany ($70 billion), Japan ($62 billion) and France ($49 billion).
More importantly, the disparity persists when accounting for population size. In 2024, pharmaceutical sales exceeded $2,000 per capita in the United States, one of the highest rates in the world. In contrast, this indicator was significantly lower in many European countries: approximately $800 per capita in Germany, $700 in France and Spain, $600 in the United Kingdom. These differences partly reflect the lack of drug price controls in the U.S. and its role as the primary revenue engine for global pharma giants.
